Molla Huq

Response to: 'Physician global assessment in systemic lupus erythematosus: can we rely on its reliability?' by Chessa et al.

Anca Askanase, Shereen Oon, Molla Huq, Alicia Calderone, Eric F Morand, Mandana Nikpour, Cynthia Aranow

Journal article  |  2022  |  Ann Rheum Dis

Response to: 'Phsician's global assessment is often useful in SLE, but not always: the case of clinical remission' by Zen et al.

Anca Askanase, Shereen Oon, Molla Huq, Alicia Calderone, Eric F Morand, Mandana Nikpour, Cynthia Aranow

Journal article  |  2022  |  Ann Rheum Dis

Correspondence to 'Time to change the primary outcome of lupus trials'

Shereen Oon, Molla Huq, Mandana Nikpour

Journal article  |  2021  |  ANNALS OF THE RHEUMATIC DISEASES

Response to: 'Achieving lupus low disease activity and remission states under belimumab in refractory systemic lupuserythematosus: time and organ involvement matter' by Sbeih et al

Mandana Nikpour, Molla Huq, Shereen Oon

Journal article  |  2020  |  ANNALS OF THE RHEUMATIC DISEASES

Incidence, Risk Factors, and Outcomes of Cancer in Systemic Sclerosis

Kathleen Morrisroe, Dylan Hansen, Molla Huq, Wendy Stevens, Joanne Sahhar, Gene-Siew Ngian, Nava Ferdowsi, Catherine Hill, Janet Roddy, Jennifer Walker, Susanna Proudman, Mandana Nikpour

Journal article  |  2020  |  ARTHRITIS CARE & RESEARCH

OBJECTIVE: To quantify the burden of cancer in systemic sclerosis (SSc). METHODS: Standardized incidence ratios (SIRs) and standar..

Effect of Removing Haemolytic and Gastrointestinal Activity from the Operational Definition of the Lupus Low Disease Activity State Implications for Use as a Trial Endpoint

Vera Golder, Rangi Kandane-Rathnayake, Molla Huq, Worawit Louthrenoo, Shue Fen Luo, Yeong-Jian Wu, Aisha Lateef, Sargunan Sockalingam, Sandra Navarra, Leonid Zamora, Laniyati Hamijoyo, Yasuhiro Katsumata, Masayoshi Harigai, Madelynn Chan, Sean O'Neill, Fiona Goldblatt, Chak Sing Lau, Zhanguo Li, Alberta Hoi, Mandana Nikpour, et al.

Conference Proceedings  |  2020  |  ARTHRITIS & RHEUMATOLOGY

Lupus Low Disease Activity State and Reduced Direct Health Care Costs in Patients With Systemic Lupus Erythematosus

Ai Li Yeo, Rachel Koelmeyer, Rangi Kandane-Rathnayake, Vera Golder, Alberta Hoi, Molla Huq, Edward Hammond, Henk Nab, Mandana Nikpour, Eric F Morand

Conference Proceedings  |  2020  |  ARTHRITIS CARE & RESEARCH

OBJECTIVE: Treat-to-target end points for systemic lupus erythematosus (SLE) have been assessed for their impact on damage accrual..

Performance of the 2017 EUSTAR activity index in an scleroderma cohort

Laura Ross, Wendy Stevens, Michelle Wilson, Molla Huq, Gemma Strickland, Jennifer Walker, Joanne Sahhar, Gene-Siew Ngian, Janet Roddy, Peter Youssef, Susanna Proudman, Mandana Nikpour

Journal article  |  2020  |  CLINICAL RHEUMATOLOGY

Assessment of disease activity in systemic sclerosis (SSc) is limited by the absence of a fully validated, multisystem measure of ..

Laboratory investigation results influence Physician's Global Assessment (PGA) of disease activity in SLE

Cynthia Aranow, Anca Askanase, Shereen Oon, Molla Huq, Alicia Calderone, Eric F Morand, Mandana Nikpour

Journal article  |  2020  |  ANNALS OF THE RHEUMATIC DISEASES

OBJECTIVE: To evaluate the impact of laboratory results on scoring of the Physician Global Assessment (PGA) of disease activity in..

The cost-effectiveness of guideline-driven use of drug-eluting stents: propensity-score matched analysis of a seven-year multicentre experience

Thathya Ariyaratne, Zanfina Ademi, Richard Ofori-Asenso, Molla M Huq, Stephen J Duffy, Bryan P Yan, Andrew E Ajani, David J Clark, Baki Billah, Angela L Brennan, Gishel New, Nick Andrianopoulos, Christopher M Reid

Journal article  |  2020  |  CURRENT MEDICAL RESEARCH AND OPINION

Background: In routine clinical practice, the implantation of a drug-eluting stent (DES) versus a bare metal stent (BMS) for percu..